HEART FAILURE AND CARDIOMYOPATHY

Incidence, clinical characteristics and outcome of congestive heart failure as the initial presentation in patients with primary hyperthyroidism

Chung-Wah Siu, Chun-Yip Yeung, Chu-Pak Lau, Annie W C Kung, Hung-Fat Tse

Heart 2007;93:483–487. doi: 10.1136/hrt.2006.100628

See end of article for authors' affiliations

Correspondence to:
Professor H-F Tse or
Professor AWC Kung,
Department of Medicine, The
University of Hong Kong,
Queen Mary Hospital, Hong
Kong, China; hftse@hkucc.
hku.hk or awckung@hkucc.
hku.hk

Accepted 18 August 2006
Published Online First
27 September 2006

Background: There are limited systematic data on the incidence, clinical characteristics and outcomes of congestive heart failure (CHF) in patients with hyperthyroidism. The aim of this study was to investigate the incidence, clinical characteristics and outcome of CHF as the initial presentation in patients with primary hyperthyroidism.

Methods: The prevalence, clinical characteristics and outcome of CHF was studied in 591 consecutive patients (mean (SD) age 45 (1) years, 140 men) who presented with primary hyperthyroidism.

Results: CHF was the presenting condition in 34 patients (5.8%) with hyperthyroidism. The presence of atrial fibrillation at presentation (OR 37.4, 95% CI 9.72 to 144.0, $p < 0.001$) was an independent predictor for the occurrence of CHF. Of the 34 patients with CHF, 16 (47%) had systolic left ventricular dysfunction with left ventricular ejection fraction (LVEF) $< 50\%$. They were predominantly male (OR 26.6, 95% CI 2.6 to 272.5, $p = 0.006$) and had a lower serum thyroxine level (OR 0.93, 95% CI 0.87 to 0.99, $p = 0.044$) than patients with preserved left ventricular systolic function. In these patients, LVEF (55 (4)% vs 30 (2)%, $p < 0.001$) and New York Heart Association functional class (1.2 (0.1) vs 2.5 (0.2), $p < 0.001$) improved significantly 3 months after achieving euthyroid status. Systolic left ventricular dysfunction (mean (SD) LVEF 38 (4)%) persisted on long-term follow-up in five patients: no clinical parameter could be identified to predict the occurrence of this persistent cardiomyopathy ($p > 0.05$).

Conclusion: CHF was the initial clinical presentation in approximately 6% of patients with hyperthyroidism, and half of them had left ventricular systolic dysfunction. Symptoms of CHF subsided and LVEF improved after treatment for hyperthyroidism. Nonetheless, one-third of these patients developed persistent dilated cardiomyopathy.

Hyperthyroidism is a common metabolic disorder with prominent cardiovascular manifestations.^{1,2} It creates a hyperdynamic circulatory state because of a marked fall in peripheral vascular resistance and an increased total blood volume and heart rate.^{2–5} These cardiovascular changes can aggravate pre-existing cardiac disease or directly lead to thyrotoxic heart disease.^{1,6} Although symptoms and signs of congestive heart failure (CHF) are common in patients with hyperthyroidism,^{2,7} dilated cardiomyopathy with impaired left ventricular systolic function is only rarely reported.^{8–11} Hyperthyroidism is a very rare ($< 1\%$) cause of dilated cardiomyopathy.¹² Nonetheless, there has been no systematic study of the incidence, clinical characteristics and outcome of heart failure caused by hyperthyroidism. The purpose of this study was to determine the incidence, clinical characteristics and outcome of heart failure in a large cohort of patients with hyperthyroidism.

METHODS

Study population

We studied 618 consecutive Chinese patients diagnosed with hyperthyroidism from January 2001 to December 2002 in the Cardiology Division, Department of Medicine and Metabolic and Endocrinology Division, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China, the only large regional general hospital to accept emergency referrals from the western region of Hong Kong Island. Patients were referred directly or from hospital wards to our thyroid and general medical outpatient clinics for treatment of primary hyperthyroidism. Data were prospectively collected

on their demographic characteristics, symptoms of heart failure and hyperthyroidism, ECG at presentation and clinical outcome during follow-up. Patients were excluded from study if they had documented pre-existing coronary artery disease, or a history of myocardial infarction, CHF and cerebrovascular and peripheral vascular disease ($n = 8$) or incomplete clinical data ($n = 12$). A further seven patients with previously diagnosed persistent atrial fibrillation in the presence of a normal thyroid function test, and who subsequently developed hyperthyroidism after treatment with amiodarone were also excluded from the analysis. A total of 591 patients were included in the final analysis.

Definitions

The diagnosis of primary hyperthyroidism was established in the presence of a serum-free thyroxine (T_4) level > 23 pmol/L, and a concomitant suppressed thyroid-stimulating hormone level < 0.03 pmol/L. A diagnosis of Graves' disease was based on the clinical presentation of hyperthyroidism, usually in the presence of a diffuse goitre with or without thyroid eye signs and positive immunological markers. Presence of CHF diagnosis was retrieved from the medical records and validated with the use of modified Framingham criteria.^{13,14} Hypertension was defined as a systolic blood pressure of ≥ 140 mm Hg, a diastolic blood pressure of ≥ 90 mm Hg, or if the patient was prescribed drugs for hypertension. Smoking status was also recorded, with patients classified as non-smoker or current smoker.

Abbreviations: CHF, congestive heart failure; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association

Table 1 Demographic characteristics of study population

	All (n = 591)	Without heart failure (n = 557)	With heart failure (n = 34)	p Value
Age, years	45 (1)	44 (1)	66 (3)	<0.01
Male	140 (24)	120 (22)	20 (59)	<0.01
Hypertension	50 (9)	39 (7)	11 (32)	<0.01
Diabetes mellitus	32 (5)	27 (5)	5 (15)	0.01
Smoking history	116 (20)	103 (18)	13 (34)	0.01
Free thyroxine, pmol/l	52 (1)	52 (1)	53 (7)	0.77
Aetiology of hyperthyroidism				
Graves' diseases	362 (61)	346 (62)	16 (47)	0.10
Toxic multinodular goitre	226 (38)	208 (37)	18 (52)	
Others	3 (1)	3 (1)	0 (0)	
Duration of symptoms of hyperthyroidism, months	35 (14)	32 (16)	39 (12)	0.53
Atrial fibrillation at presentation	82 (14)	50 (9)	32 (94)	<0.01
Heart rate at presentation, bpm	110 (5)	100 (3)	138 (3)	<0.01

Values are in n (%) or mean (SEM).

Transthoracic echocardiography

Two-dimensional and M-mode transthoracic echocardiographic examinations were performed in all subjects using the System V machine (GE Medical System, Waukesha, Wisconsin, USA) with a 3.5 MHz transducer, according to the recommendations of the American Society of Echocardiography.¹⁵ Left ventricular systolic dysfunction was defined as left ventricular ejection fraction (LVEF) $\leq$ 50%. All studies were performed and analysed by the same experienced operator who was unaware of the patients' clinical status.

Follow-up

In patients with hyperthyroidism and CHF, initial transthoracic echocardiography was performed after stabilisation of heart failure symptoms and adequate ventricular rate control in those with atrial fibrillation. Clinical and ECG evaluation, laboratory measurements and transthoracic echocardiography were repeated 3 months after completion of treatment (antithyroid drugs or radioactive iodine-131) for hyperthyroidism to achieve euthyroid status. In patients in whom ventricular systolic dysfunction persisted after achievement of euthyroid status, cardiac catheterisation or exercise thallium was performed to

exclude concomitant coronary artery disease. Transthoracic echocardiography was also repeated at 12 months after establishment of a euthyroid state to detect delayed recovery of left ventricular systolic dysfunction.

Statistical analysis

Continuous variables are expressed as mean $\pm$ 1 SEM. Statistical comparisons were performed using Student's *t* test or Fisher's exact test, as appropriate. A logistic regression model was applied to determine clinical predictors for the occurrence of CHF and left ventricular systolic dysfunction in patients with hyperthyroidism. Multivariate analyses were performed with an enter regression model, in which each variable with a $p \leq 0.1$ (based on the univariate analysis) was entered into the model. Calculations were performed using SPSS software (V.10.0). $p < 0.05$ was considered significant.

RESULTS

Incidence of CHF

Table 1 presents the baseline demographic and clinical variables of 591 consecutive patients diagnosed with hyperthyroidism. Their mean age was 45 (1) years (range 18–97 years), and 140 patients (24%) were male. All patients were Chinese in origin. A total of 34 patients (5.8%) had symptoms of CHF at presentation. The Hong Kong West Island adult population remained stable at approximately 300 000 during the study period giving an annual incidence of CHF related to hyperthyroidism of 5.6 per 100 000 general population.

Clinical characteristics of CHF

Patients with CHF were older, most of them were male, had a higher prevalence of a history of hypertension and diabetes, and cigarette smoking, and had a higher incidence of atrial fibrillation and resting heart rate at presentation compared with patients without CHF (table 1; $p < 0.05$). There were no significant differences in the duration of symptoms of hyperthyroidism, serum free T_4 level or the incidence of Graves' disease (table 1; $p > 0.05$). In multivariate analysis, only the presence of atrial fibrillation at presentation (OR 37.4, 95% CI 9.72 to 144.0, $p < 0.001$) was an independent predictor for the occurrence of CHF in patients with hyperthyroidism.

In the 34 patients who presented with symptoms of CHF, an echocardiogram showed no evidence of marked valvular lesion, pericardial disease, or hypertrophic or infiltrative cardiomyopathy, and 16 (47%) had left ventricular systolic dysfunction with LVEF $\leq$ 50%. None had a history of alcohol or illicit drug misuse or exposure to cardiotoxic agents. Patients with left

Table 2 Demographic characteristics and clinical parameters of patients with heart failure, with or without left ventricular systolic dysfunction at presentation

	LV systolic dysfunction		p Value
	Absent (n = 18)	Present (n = 16)	
Age, years	72 (3)	58 (4)	0.03
Male	6 (33)	14 (88)	<0.01
Hypertension	3 (17)	8 (50)	0.07
Diabetes mellitus	3 (17)	2 (13)	1.0
Smoking history	4 (22)	9 (56)	0.07
Free thyroxine, pmol/l	66 (12)	39 (4)	0.04
Aetiology of hyperthyroidism			
Graves' diseases	11 (61)	5 (31)	0.10
Toxic multinodular goitre	7 (39)	11 (69)	
Duration of symptoms of hyperthyroidism, days	40 (25)	38 (16)	0.85
Atrial fibrillation	18 (100)	14 (88)	0.21
Heart rate, bpm	140 (5)	137 (9)	0.79
LV end-diastolic dimension, cm	4.3 (0.1)	5.3 (0.2)	<0.01
LVEF	62 (2)	29 (2)	<0.01

LV, left ventricle; LVEF, left ventricular ejection fraction.
Values are in n (%) or mean (SEM).

Figure 1 Serial changes in left ventricular ejection fraction (LVEF) in patients with (▲) or without (□) persistent left ventricular systolic dysfunction at presentation, 3 months and 12 months after achieving euthyroid status.

ventricular systolic dysfunction were significantly younger, with a higher prevalence of males, lower serum free T_4 level and LVEF and a larger left ventricular end-diastolic dimension compared with patients without left ventricular systolic dysfunction (table 2; $p<0.05$). There were no significant differences in the prevalence of hypertension, diabetes and smoking, duration of symptoms of hyperthyroidism, incidence of atrial fibrillation and resting heart rate at presentation or incidence of antithyroid antibodies (table 2; $p>0.05$). In multivariate analysis, male sex (OR 26.6, 95% CI 2.6 to 272.5, $p=0.006$) and lower serum T_4 level (OR 0.93, 95% CI 0.87 to 0.99, $p=0.044$) were independent predictors of left ventricular systolic dysfunction with $LVEF \leq 50\%$ in patients with hyperthyroidism.

Clinical outcome

In the 34 patients with CHF, all achieved euthyroid status with either radioactive iodine ($n=21$) or carbimazole ($n=12$)

treatment, except one patient who died of refractory heart failure during the initial presentation.

In the 18 patients with $LVEF \geq 50\%$, all had atrial fibrillation at presentation. The time to achieve satisfactory resting mean heart rate control (<90 bpm) was 3.5 (0.5) days. Symptoms of heart failure subsided after treatment with diuretics, β -blocker and carbimazole at initial presentation. Spontaneous sinus conversion from atrial fibrillation was observed in 8 of 18 patients (44%) at a mean of 121 (46) days after treatment of hyperthyroidism. During a mean follow-up of 42 (6) months, none reported any symptoms of CHF, including the 10 patients in whom atrial fibrillation persisted.

In the remaining 15 patients with $LVEF \leq 50\%$, 13 had atrial fibrillation at presentation. The time to achieve satisfactory mean resting heart rate control (<90 bpm) was 4.7 (0.8) days. Spontaneous sinus conversion from atrial fibrillation was observed in 6 of 13 patients (46%) at a mean of 328 (131) days after treatment of hyperthyroidism. Three months after achieving euthyroid status, LVEF (55 (4)% vs 30 (2)%, $p<0.001$) and New York Heart Association (NYHA) functional class (1.2(0.1) vs 2.5 (0.2), $p<0.001$) had significantly improved compared with initial presentation. In 10 patients (67%), LVEF had completely recovered (65 (2)% vs 32 (2)%, $p<0.01$, fig 1) and none of them reported any symptoms of CHF 3 months after achieving euthyroid status. In the remaining five patients (33%), left ventricular systolic dysfunction persisted with $LVEF \leq 50\%$, although LVEF (36 (4)% vs 26 (5)%, $p<0.01$, fig 1) and NYHA functional class (1.4 (1) vs 3.2 (1), $p=0.03$) had significantly improved.

There were no significant differences ($p>0.05$) in the demographic features of patients with or without persistent left ventricular systolic dysfunction in terms of duration of symptoms of hyperthyroidism, incidence of atrial fibrillation and resting heart rate, serum free T_4 level, incidence of Graves' disease, LVEF and left ventricular end-diastolic dimension at presentation of hyperthyroidism and time to achieve satisfactory heart rate (table 3). In addition, among those patients with atrial fibrillation at presentation, there were no significant differences in the percentage of patients with spontaneous conversion to sinus rhythm (50% vs 44%, $p=1.0$) and their time to conversion (265 (260) days vs 361 (67) days, $p=0.3$) between patients with and without persistent left ventricular systolic dysfunction.

In five patients with persistent left ventricular systolic dysfunction after achieving a euthyroid state, a coronary angiogram was normal in four, and a thallium SPECT scan in the remaining patient showed no evidence of myocardial ischaemia. At 1-year follow-up, three patients were in sinus rhythm and two had persistent atrial fibrillation with satisfactory heart rate control (average heart rate <80 bpm at 24 h ECG recording). Despite optimal medical treatment for heart failure in these patients, including use of an ACE inhibitor ($n=5$), digoxin ($n=4$), frusemide ($n=4$), β -blocker ($n=3$), spironolactone ($n=2$) and angiotensin II antagonists ($n=2$), there was no further improvement in LVEF at 1 year compared with those at 3 months after achieving a euthyroid state (36 (3)% vs 38 (4)%, $p=0.29$, fig 1).

DISCUSSION

Although an increased workload caused by the induction of a hyperdynamic circulation during hyperthyroidism can trigger the onset of heart failure in patients with pre-existing heart disease, it may also directly induce CHF.²⁻⁷ Nevertheless, there are limited data on the incidence of CHF in patients with hyperthyroidism. This study showed that 6% of patients with hyperthyroidism developed CHF and the annual incidence is 5.6 per 100 000 general population. Consistent with previous

Table 3 Demographic characteristics and clinical parameters of patients with and without persistent left ventricular systolic dysfunction

	Persistent LV systolic dysfunction		p Value
	Absent (n=10)	Present (n=5)	
Age, years	63 (5)	56 (8)	0.43
Male	8 (80)	5 (100)	0.52
Hypertension	4 (40)	80 (4)	0.28
Diabetes mellitus	2 (20)	0 (0)	0.52
Smoking history	4 (40)	3 (60)	0.61
Free thyroxine, pmol/l	41 (5)	38 (6)	0.81
Aetiology of hyperthyroidism			
Graves' diseases	4 (40)	1 (20)	0.60
Toxic multinodular goitre	6 (60)	4 (80)	
Duration of symptoms of hyperthyroidism, days	37 (12)	40 (13)	0.78
Atrial fibrillation at presentation	9 (90)	4 (80)	1.00
Heart rate at presentation bpm	139 (12)	122 (3)	0.21
Time to achieve resting heart rate control (<90 /min), days	4.6 (0.6)	4.8 (1.4)	0.90
LV end-diastolic dimension at presentation, cm	5.4 (0.3)	5.8 (0.6)	0.49
LVEF at presentation	32 (2)	26 (5)	0.16
Time to achieve euthyroid status, days	138 (53)	113 (70)	0.79

LV, left ventricle; LVEF, left ventricular ejection fraction. Values are in n (%) or mean (SEM).

studies,¹⁶ this study showed that elderly patients with pre-existing hypertension or with risk factors for coronary artery disease, such as smoking and diabetes, were more susceptible to adverse haemodynamic changes related to hyperthyroidism and developed CHF. In addition, the occurrence of atrial fibrillation could worsen cardiac function, and was an independent predictor for the development of CHF.

In this study, about half of the patients who presented with CHF had normal LVEF. Their heart failure symptoms may have reflected a congestive circulation secondary to excess sodium and fluid retention related to hyperthyroidism or caused by diastolic heart failure triggered by sustained tachycardia and/or atrial fibrillation.^{2 16 17} These patients responded well to treatment with diuretics and rate control treatment with a β -blocker.

More importantly, left ventricular systolic dysfunction was observed in the remaining patients with CHF at presentation. Compared with patients in whom left ventricular function was preserved, those with left ventricular systolic dysfunction showed a male predominance and had a significantly lower serum T₄ level at presentation. Although the exact mechanism remains unclear, multiple factors are likely to contribute to the development of left ventricular systolic dysfunction in patients with hyperthyroidism. First, chronic persistent tachyarrhythmias caused by a combination of hyperthyroidism and atrial fibrillation can lead to CHF due to tachycardia-induced cardiomyopathy. Despite this, we found no significant difference in the duration of symptoms of hyperthyroidism, incidence of atrial fibrillation and resting heart rate at presentation between patients with and without left ventricular systolic dysfunction. Furthermore, in those patients with atrial fibrillation, the time to achieve satisfactory heart rate control, percentage of patients with spontaneous conversion to sinus rhythm, and their time to conversion were similar between the two groups. In the five patients with persistent left ventricular systolic dysfunction, three were in sinus rhythm and two had persistent atrial fibrillation with satisfactory heart rate control at 1-year follow-up after establishment of a euthyroid state. Therefore, in approximately two-thirds of patients with left ventricular dysfunction at presentation, sustained tachyarrhythmias and atrial fibrillation contributed to the development of left ventricular dysfunction which recovered after rate or rhythm control of atrial fibrillation. In the remaining one-third, there was only partial recovery of left ventricular dysfunction despite successful rate or rhythm control of tachyarrhythmias and atrial fibrillation by drugs and treatment of hyperthyroidism. This suggests that other mechanisms may contribute to the development of left ventricular dysfunction in these patients. Second, the presence of concurrent autoimmune myocarditis related to Graves' disease has been suggested to be a contributing factor.¹⁸ Nonetheless, several histological studies in patients with dilated cardiomyopathy complicated hyperthyroidism showed no evidence of active myocarditis.¹⁹⁻²¹ In this study, there was no significant difference in the incidence of Graves' disease between patients with and without left ventricular systolic dysfunction. Finally, direct myocardial damage in hyperthyroidism has also been shown by radioactive²² or magnetic resonance²³ cardiac imaging. Interestingly, a lower rather than a higher serum T₄ level was associated with the development of left ventricular systolic dysfunction in this study. Although there was no significant difference in the duration of onset of symptoms of hyperthyroidism, patients with left ventricular systolic dysfunction may have a more prolonged duration of subclinical hyperthyroidism, possibly because of a lower serum T₄ level as in elderly patients with multinodular goitre. We found that male patients were more likely to develop left ventricular systolic dysfunction with hyperthyroidism. In experimental studies, male animals were more susceptible to the cardiotoxic effects

of overexpression of β -adrenergic receptors than female animals, possibly because of upregulation of a hypertrophy-related gene by androgens.²⁴ This increased cardiac sensitivity to β -adrenergic stimulation in males may account for their higher incidence of left ventricular systolic dysfunction related to hyperthyroidism.

The availability of effective treatment for primary hyperthyroidism has led to the widespread belief that it is a benign disorder and that all the associated adverse effects are reversible with no long-term sequelae. Although prior case studies have shown that left ventricular function improves in the majority of patients after treatment of hyperthyroidism, persistent dilated cardiomyopathy was observed in a significant proportion of patients.^{8-11 20 21} This is the first systematic study to show that persistent and potentially fatal dilated cardiomyopathy developed in approximately 1% (6/519 patients, including one patient who died of refractory heart failure) of patients with primary hyperthyroidism. Up to one-third of patients with left ventricular systolic dysfunction at presentation had persistent dilated cardiomyopathy during long-term follow-up. Long-term follow-up is thus vital to detect the persistence of cardiomyopathy in those patients with hyperthyroidism who have left ventricular systolic dysfunction at initial presentation.

Study limitation

In this study, echocardiography was performed only in patients with signs and symptoms of CHF. The incidence of subclinical left ventricular systolic dysfunction in those patients without CHF thus remains unknown.

Authors' affiliations

Chung-Wah Siu, Chun-Yip Yeung, Chu-Pak Lau, Annie W C Kung, Hung-Fat Tse, Cardiology Division, Department of Medicine and Metabolic and Endocrinology Division, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China

Competing interests: None.

REFERENCES

- Polikar R, Burger AG, Scherrer U, et al. The thyroid and the heart. *Circulation* 1993;87:1435-41.
- Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. *N Engl J Med* 2001;344:501-9.
- Klein I. Thyroid hormone and the cardiovascular system. *Am J Med* 1990;88:631-7.
- Kahaly GJ, Kampmann C, Mohr-Kahaly S. Cardiovascular hemodynamics and exercise tolerance in thyroid disease. *Thyroid* 2002;12:473-81.
- Feldman T, Borow KM, Sarne DH, et al. Myocardial mechanics in hyperthyroidism: importance of left ventricular loading conditions, heart rate and contractile state. *J Am Coll Cardiol* 1986;7:967-74.
- Forfar JC, Muir AL, Sowers SA, et al. Abnormal left ventricular function in hyperthyroidism. Evidence for a possible reversible cardiomyopathy. *N Engl J Med* 1982;307:1165-70.
- Polikar R, Burger AG, Scherrer U, et al. The thyroid and the heart. *Circulation* 1993;87:1435-41.
- Shirani J, Barron MM, Pierre-Louis ML, et al. Congestive heart failure, dilated cardiac ventricles, and sudden death in hyperthyroidism. *Am J Cardiol* 1993;72:365-8.
- Umpierrez GE, Challapalli S, Patterson C. Congestive heart failure due to reversible cardiomyopathy in patients with hyperthyroidism. *Am J Med Sci* 1995;310:99-102.
- Watanabe E, Ohsawa H, Noike H, et al. Dilated cardiomyopathy associated with hyperthyroidism. *Intern Med* 1995;34:762-7.
- Boccalandro C, Boccalandro F, Orlander P, et al. Severe reversible dilated cardiomyopathy and hyperthyroidism: case report and review of literature. *Endocr Pract* 2003;9:140-6.
- Kasper EK, Agema WR, Hutchins GM, et al. The causes of dilated cardiomyopathy: a clinicopathologic review of 673 consecutive patients. *J Am Coll Cardiol* 1994;23:586-90.
- Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. *Circulation* 1998;98:2282-9.
- Redfield MM, Jacobsen SJ, Burnett JC Jr, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. *JAMA* 2003;289:194-202.
- Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of

- Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. *J Am Soc Echocardiogr* 1989;**2**:358–67.
- 16 Klein I, Ojamaa K. Thyrotoxicosis and the heart. *Endocrinol Metab Clin North Am* 1998;**27**:51–62.
 - 17 DeGroot WJ, Leonard JJ. Hyperthyroidism as a high cardiac output state. *Am Heart J* 1970;**79**:265–75.
 - 18 Koshiyama H, Sellitti DF, Akamizu T, et al. Cardiomyopathy associated with Graves' disease. *Clin Endocrinol (Oxf)*, 1996;**45**:111–16.
 - 19 Sachs RN, Vignot M, Modigliani E, et al. Absence of ultra-structural histological lesions of the myocardium in cardiac insufficiency of hyperthyroidism. *Ann Med Interne* 1986;**137**:375–8.
 - 20 Ebisawa K, Ikeda U, Murata M, et al. Irreversible cardiomyopathy due to thyrotoxicosis. *Cardiology* 1994;**84**:274–7.
 - 21 Fatourehchi V, Edwards WD. Graves' disease and low-output cardiac dysfunction: implications for autoimmune disease in endomyocardial biopsy tissue from eleven patients. *Thyroid* 2000;**10**:601–5.
 - 22 Marti V, Ballester M, Rigla M, et al. Myocardial damage does not occur in untreated hyperthyroidism unless associated with congestive heart failure. *Am Heart J* 1997;**134**:1133–7.
 - 23 Matsuoka H, Hamada M, Honda T, et al. Precise assessment of myocardial damage associated with secondary cardiomyopathies by use of Gd-DTPA-enhanced magnetic resonance imaging. *Angiology* 1993;**44**:945–50.
 - 24 Gao XM, Agrotis A, Autelitano DJ, et al. Sex hormones and cardiomyopathic phenotype induced by cardiac beta 2-adrenergic receptor overexpression. *Endocrinology* 2003;**144**:4097–105.

IMAGES IN CARDIOLOGY

Dynamic collateral coronary circulation: angiographic evidence

A 54-year-old man was admitted to our cardiovascular department because of angina on effort (Canadian class II). Angina was characterised by marked variability of the threshold and occasional episodes of rest angina. He was hypertensive, was an ex-smoker and had diabetes. In 1998, he had an inferolateral myocardial infarction and was administered medical treatment including aspirin and β -blockers. He remained asymptomatic on medical treatment up to 6 months prior to admission, when he had recurrence of angina on effort in spite of medical treatment including aspirin, β -blockers, sartanic and statin. During current hospital stay, an echocardiogram revealed mild impairment of left ventricular function (ejection fraction 45%), inferolateral akinesia and moderate mitral regurgitation. A dobutamine stress test showed viable myocardium in the akinetic region. The patient

underwent coronary angiography, which revealed proximal occlusion of the left circumflex artery of small size, proximal occlusion of the right coronary artery (RCA) and normal left anterior descending artery (LAD). Mild opacification of distal RCA was noted through collateral circulation originating from the septal branches of LAD (panel A). Reopening of the RCA was then attempted using a bilateral femoral approach with cannulation of the RCA by a guiding catheter and of the left coronary artery by a diagnostic catheter. A Pilot 200 guidewire (Guidant Corp, Santa Clara, California, USA) and an over the wire balloon 1.5/20 mm (Maverick 2, Boston Scientific Scimed, Maple Grove, Minnesota, USA) were initially used. Immediately prior to wire advancement across the occlusion, re-injection of the contrast medium into the RCA showed a striking improvement of collateral circulation from Rentrop class 1 to Rentrop class 3, and full

opacification of posterior descending, posterolateral branch and distal part of the RCA near to the occlusion point (panel B). Notably, no intracoronary nitrates were administered due to low arterial pressure (90/60 mm Hg) since the start of the procedure. This sudden change of collateral function helped operators in wire advancement through the occlusion and entry in the distal true lumen. After multiple balloon dilatation and deployment of three drug-eluting stents (Taxus, Boston Scientific, Natick, Massachusetts, USA), the RCA was reconstructed and angiographic result was optimal (panel C). Dynamic collateral coronary circulation in man has been previously demonstrated using non-invasive techniques, and well explains the variability of anginal threshold on effort. This is the first angiographic documentation that collateral circulation in man can be extremely dynamic.

Giampaolo Niccoli, Micaela Conte, Filippo Crea
gniccoli73@hotmail.it

doi: 10.1136/hrt.2006.096867

Panel A Coronary angiogram in left anterior oblique view showing the proximal occlusion of the right coronary artery (RCA) and collateral circulation from septal branches of the left anterior descending artery (LAD), with mild opacification of the distal RCA (Rentrop 1). White arrow points to the LAD.

Panel B Coronary angiogram in left anterior oblique view showing a sudden variation of collateral circulation to the distal right coronary artery (RCA), with good opacification of the RCA branches (Rentrop 3). White arrows point to the left anterior descending artery and the RCA.

Panel C Coronary angiogram in left anterior oblique view showing the final angiographic result after multiple drug-eluting stent deployment.